SRSD 101
Alternative Names: SRSD-101Latest Information Update: 29 Jul 2024
At a glance
- Originator Sirius Therapeutics
- Class Antihyperlipidaemics; Small interfering RNA
- Mechanism of Action PCSK9 protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Dyslipidaemias
Most Recent Events
- 29 Jul 2024 Phase-I clinical trials in Dyslipidaemias in China (Parenteral)
- 15 Nov 2023 Preclinical trials in Dyslipidaemias in USA (Parenteral), prior to November 2023 (Sirius Therapeutics pipeline, November 2023)
- 15 Nov 2023 NMPA approves the IND application of SRSD 101 for Dyslipidaemias